Last reviewed · How we verify
Placebo to match PEG-Tα1
This is a placebo control formulation designed to match the appearance and administration characteristics of PEG-Tα1 (pegylated thymosin alpha 1) for blinded clinical trial purposes.
At a glance
| Generic name | Placebo to match PEG-Tα1 |
|---|---|
| Sponsor | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo formulations in clinical trials are inert preparations that mimic the active drug's physical properties, route of administration, and dosing schedule to maintain blinding and reduce bias. This specific placebo is engineered to match PEG-Tα1, a pegylated immunomodulatory peptide, allowing for proper control comparisons in phase 3 trials without conveying the active drug's therapeutic effects.
Approved indications
Common side effects
Key clinical trials
- Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B (PHASE2)
- Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to match PEG-Tα1 CI brief — competitive landscape report
- Placebo to match PEG-Tα1 updates RSS · CI watch RSS
- Jiangsu Hansoh Pharmaceutical Co., Ltd. portfolio CI